Validation of the Treatment Satisfaction Questionnaire for Medication in patients with cystic fibrosis

Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
Antoine RegnaultMuriel Viala-Danten

Abstract

Our objective was to confirm the measurement properties of the Treatment Satisfaction Questionnaire with Medication (TQSM) in patients with cystic fibrosis (CF) receiving inhaled antibiotics. The TSQM was included in the EAGER study, a clinical trial comparing a nebulized and a dry powder device for inhaled tobramycin in a CF population with chronic Pseudomonas aeruginosa (Pa) lung infection, aged 6 years and above (N=553). Reliability and validity of the questionnaire were investigated using Cronbach's α and multitrait-multimethod approach. The TSQM demonstrated very good reliability and construct validity: all Cronbach's α were above 0.86 and all items met the convergent and discriminant validity criteria. In multivariate regressions, higher patient satisfaction and lower perceived impact of side-effects were associated with better treatment compliance. The TSQM showed very good measurement properties that strongly support its use to assess satisfaction of patients with CF taking inhaled antibiotics.

References

May 15, 1996·American Journal of Epidemiology·M Corey, V Farewell
Jul 29, 2003·The European Respiratory Journal·J L CampbellM R Partridge
Mar 1, 1959·Psychological Bulletin·D T CAMPBELL, D W FISKE
May 29, 2004·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Richard Shikiar, Anne M Rentz
Nov 4, 2005·The New England Journal of Medicine·Ronald J Campbell
Dec 13, 2005·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Mark J AtkinsonSteven L Hass
Jun 21, 2007·American Journal of Clinical Pathology·Bobbi PrittWashington Winn
Jul 27, 2007·Proceedings of the American Thoracic Society·Christopher H Goss, Alexandra L Quittner
Feb 2, 2008·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Joyce A CramerPeter K Wong
Oct 28, 2008·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Gregory S SawickiWalter M Robinson
Jun 30, 2009·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Harry HeijermanUNKNOWN consensus working group
Nov 16, 2010·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Michael W KonstanDavid E Geller

❮ Previous
Next ❯

Citations

Apr 11, 2015·International Journal of Health Care Quality Assurance·Bahari Mohamed, Noor Azlinna Azizan
Jul 2, 2016·Multiple Sclerosis : Clinical and Laboratory Research·Patrick VermerschPatricia K Coyle
Jun 9, 2016·Revista latino-americana de enfermagem·Ana Carolina Sauer LiberatoMaria Cecília Bueno Jayme Gallani
Dec 11, 2013·Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine·John LamMichael D Parkins
Dec 18, 2019·The Cochrane Database of Systematic Reviews·Sally PalserAlan R Smyth
Apr 26, 2017·The Cochrane Database of Systematic Reviews·Simon C Langton Hewer, Alan R Smyth
Oct 31, 2018·The Cochrane Database of Systematic Reviews·Sherie SmithEdward Charbek
Apr 3, 2018·The Cochrane Database of Systematic Reviews·Sherie SmithKate H Regan
Mar 7, 2020·Interactive Journal of Medical Research·Kathryn Volpicelli LeonardLeslie Beth Herbert

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CFTR Mutant Structural Therapy

Over 1700 different mutations in the CFTR genes have been shown to cause cystic fibrosis. Here is the latest research on structural therapy for CFTR mutants.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.